Profil Efek Samping Penggunaan Antiretroviral Pada Penderita Hiv/Aids Di Poliklinik VCT Di Kota Mataram Tahun 2019

Pertiwi, Mitha Yunda; Wardani, Indah Sapta; Wedayani, Anak Agung Ayu Niti

doi:10.29303/jku.v9i4.443

Cited by 1 publication

(1 citation statement)

References 14 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found the 3 most common LTE side effects among people living with HIV in this study, that were headache, nausea, and nightmares. This was slightly different from a study finding in Mataram that LTE side effects among people living with HIV were weakness, dizziness, and vomiting where these side effects were still in the mild category [37], while another study in India found the most common side effect of LTE among people living with HIV was drowsiness, followed by headaches and nightmares [21]. In general, the most common side effects experienced by people living with HIV in this study were symptoms due to central nervous system disorder.…”

Section: Discussioncontrasting

confidence: 95%

Tenofovir Lamivudine Efavirenz Side Effect and Its Efficacy Among People Living with HIV in Jayapura

Adiningsih¹,

Widiyanti²,

Rokhmad³

2023

Proceedings of the 1st International Conference for Health Research – BRIN (ICHR 2022)

View full text Add to dashboard Cite

Tenofovir lamivudine efavirenz (TLE) as a single-tablet regimen is preferred to the long use of combination antiretroviral therapy. TLE is safer than another antiretroviral drug regimen for first-line of Human immunodeficiency virus (HIV) treatment. However, there is little information about the side effects of TLE during first-time therapy among people living with HIV in Jayapura. This study aimed to assess the TLE side effect and its efficacy among people living with HIV in Jayapura, Papua. This was a cross-sectional study involving 77 people living with HIV who took a single-tablet regimen of TLE for one to two years of antiretroviral therapy, comply the inclusion criteria, and provided consent to participate. Data collection was conducted through CD4 + tests, medical records, and interviews at Jayapura City Hospital. Descriptive statistics were used to determine the proportion of relevant variables. The results described that most groups of people living with HIV were adult group (93.5%), female (61.0%), Papuan (64.9%), had WHO clinical stage III-IV (67.5%), had CD4 + counts < 350 cell/µL in the early therapy (79.2%) and CD4 + counts ≥ 350 cell/µL at the time of the study (57.1%), and experienced TLE side effect (71.4%). The most symptoms of TLE side effects among people living with HIV were headache (61.8%), nausea (34.5%), and nightmare (29.1%). As many as 70.9% of people living with HIV experienced these symptoms for less than 2 weeks. TLE was still effective, indicated by an increase of CD4 + cell count average from 242.6 cell/mm 3 at the early therapy to 436.6 cell/mm 3 during this study, with good adherence to drug therapy (>95% adherence) by 53.2% of people living with HIV. The side effects of TLE can still be tolerated by most people living with HIV so the therapy can be continued without altering the regimen.

show abstract

Section: Discussioncontrasting

confidence: 95%